Patents by Inventor John McWhirter
John McWhirter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240146439Abstract: Systems, methods, and computer-readable media for deterministic dynamic shaping of traffic of a communication network are provided.Type: ApplicationFiled: August 29, 2023Publication date: May 2, 2024Inventors: Jamie Aaron Brown, Stephen Russell McWhirter, Elya Joseph Kapelyan, Craig John Mohan
-
Publication number: 20240099279Abstract: Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a humanized or human T cell receptor (TCR) comprising a variable domain encoded by (a) at least one human TCR variable region ? gene segment and a (human) TCR ? constant region gene sequence and/or (b) or at least one human TCR variable region ? gene segment and a (human) TCR ? constant region gene sequence. Also provided are embryos, tissues, and cells expressing the same. Methods for making a genetically engineered animal that expresses the humanized or human ? and/or ? TCR are also provided. Methods for using the genetically engineered animals that mount a substantially humanized T cell immune response for developing human therapeutics are also provided.Type: ApplicationFiled: September 22, 2023Publication date: March 28, 2024Inventors: Naxin Tu, John McWhirter, Chunguang Guo, Cagan Gurer, Vera Voronina, Lynn Macdonald, Andrew J. Murphy
-
Patent number: 11932859Abstract: Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a gRNA-Cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a gRNA-Cas complex) can create double strand breaks in dsDNA in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. Assembly using the method described herein can assemble any nucleic acids having overlapping sequences or can use a joiner oligo to assemble sequences without complementary ends.Type: GrantFiled: March 11, 2020Date of Patent: March 19, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Chris Schoenherr, John McWhirter, Corey Momont, Caitlin L. Goshert, Lynn Macdonald, Gregg S. Warshaw, Jose F. Rojas, Ka-Man Venus Lai, David M. Valenzuela, Andrew J. Murphy
-
Publication number: 20240076613Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.Type: ApplicationFiled: November 6, 2023Publication date: March 7, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Marine Prissette, Matthew Koss, Mathieu Desclaux, John McWhirter, Arijit Bhowmick, David Frendewey, Brian Zambrowicz, Claudia Racioppi
-
Publication number: 20240065239Abstract: Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g., the testing of the pharmacokinetic and/or pharmacodynamic properties of such therapeutic agents and dosing regimens). Also provided herein are methods of using such mice, cells from such mice, methods of making such mice, and ES cells comprising the same genetic modifications as such mice. Provided herein are methods and compositions related to mice that express human or humanized Foot receptors (FcaR) from an FcaR locus positioned in the mouse leukocyte receptor complex (LRC). In certain embodiments, such mice are useful for in vivo testing of therapeutic agents comprising a human IgA Fc (e.g.Type: ApplicationFiled: December 15, 2021Publication date: February 29, 2024Inventors: John McWhirter, Naxin Tu, Andrew J. Murphy, Lynn MacDonald
-
Publication number: 20240065238Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.Type: ApplicationFiled: April 20, 2023Publication date: February 29, 2024Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter
-
Patent number: 11845957Abstract: BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.Type: GrantFiled: June 12, 2020Date of Patent: December 19, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Marine Prissette, Matthew Koss, Mathieu Desclaux, John McWhirter, Arijit Bhowmick, David Frendewey, Brian Zambrowicz, Claudia Racioppi
-
Publication number: 20230310215Abstract: A patient interface device for use with a laser surgery apparatus, the device including an upper assembly and a lower assembly attached to the upper assembly. The device including a spherical-like object that engages the lower assembly so that an enclosed volume is defined between the spherical-like object, the lower assembly and the upper assembly, wherein a first liquid substantially fills the enclosed volume. The device further including a channel that contains a second fluid that is exposed to ambient atmosphere.Type: ApplicationFiled: February 20, 2023Publication date: October 5, 2023Applicant: Lensar, Inc.Inventors: E. Valaski Teuma, John McWhirter, Richard Ty Olmstead
-
Publication number: 20230277692Abstract: Provided herein are methods and compositions related to the in vivo testing of therapeutic agents comprising a human Fc in genetically modified rodents (e.g., the testing of the pharmacokinetic and/or pharmacodynamic properties of such a therapeutic agent in genetically modified rodents). In some embodiments the genetically modified rodents express antibodies comprising a human Fc (e.g., a human IgG1 Fc, a human IgG4 Fc). In some embodiments, the rodents express fully human antibodies (i.e., antibodies having human heavy chains and human light (? or ?) chains). In certain embodiments the genetically modified rodents comprise one or more Fc receptors with a human extracellular domain (e.g., a Neonatal Fc Receptor (FcRn), a ?-2-microglobulin polypeptide (?2M), a Fc ? receptor 1 ? (Fc?R1?), a Fc ? receptor 1 alpha (Fc?R1a), a Fc gamma receptor 2a (Fc?R2a), a Fc gamma receptor 2b (Fc?R2b), a Fc gamma receptor 3a (Fc?R3a), a Fc gamma receptor 3b (Fc?R3b), a Fc gamma receptor 2c (Fc?R2c)).Type: ApplicationFiled: December 27, 2022Publication date: September 7, 2023Inventors: Vera Voronina, Corey Momont, John McWhirter, Naxin Tu, Lynn MacDonald, Andrew J. Murphy
-
Patent number: 11666040Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.Type: GrantFiled: April 15, 2020Date of Patent: June 6, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter
-
Patent number: 11583446Abstract: A patient interface device for use with a laser surgery apparatus, the device including an upper assembly and a lower assembly attached to the upper assembly. The device including a spherical-like object that engages the lower assembly so that an enclosed volume is defined between the spherical-like object, the lower assembly and the upper assembly, wherein a first liquid substantially fills the enclosed volume. The device further including a channel that contains a second fluid that is exposed to ambient atmosphere.Type: GrantFiled: May 14, 2018Date of Patent: February 21, 2023Assignee: Lensar, Inc.Inventors: E. Valaski Teuma, John McWhirter, Richard Ty Olmstead
-
Patent number: 11576984Abstract: Provided herein are methods and compositions related to the in vivo testing of therapeutic agents comprising a human Fc in genetically modified rodents (e.g., the testing of the pharmacokinetic and/or pharmacodynamic properties of such a therapeutic agent in genetically modified rodents). In some embodiments the genetically modified rodents express antibodies comprising a human Fc (e.g., a human IgG1 Fc, a human IgG4 Fc). In some embodiments, the rodents express fully human antibodies (i.e., antibodies having human heavy chains and human light (? or ?) chains). In certain embodiments the genetically modified rodents comprise one or more Fc receptors with a human extracellular domain (e.g., a Neonatal Fc Receptor (FcRn), a ?-2-microglobulin polypeptide (?2M), a Fc ? receptor 1? (Fc?R1?), a Fc ? receptor 1 alpha (Fc?R1a), a Fc gamma receptor 2a (Fc?R2a), a Fc gamma receptor 2b (Fc?R2b), a Fc gamma receptor 3a (Fc?R3a), a Fc gamma receptor 3b (Fc?R3b), a Fc gamma receptor 2c (Fc?R2c)).Type: GrantFiled: March 25, 2019Date of Patent: February 14, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Vera Voronina, Corey Momont, John McWhirter, Naxin Tu, Lynn MacDonald, Andrew J. Murphy
-
Patent number: 11559050Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.Type: GrantFiled: December 4, 2019Date of Patent: January 24, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter
-
Patent number: 11528895Abstract: The invention provides a genetically modified non-human animal that comprises in its genome unrearranged T cell receptor variable gene loci, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified non-human animal and methods of making the same. Various methods of using the genetically modified non-human animal are also provided.Type: GrantFiled: July 14, 2015Date of Patent: December 20, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Andrew J. Murphy, John McWhirter, Naxin Tu, Vera Voronina, Cagan Gurer, Karolina Meagher, Sean Stevens
-
Publication number: 20220394959Abstract: Mice, tissues, cells, and genetic material are provided that comprise a humanized heavy chain immunoglobulin locus, a humanized light chain locus that expresses a universal light chain, and a gene encoding an ADAM6 or ortholog or homolog or functional fragment thereof. Mice are provided that express humanized heavy chains comprising human variable domains, and that express humanized light chains comprising human variable domains wherein the light chains are derived from no more than one, or no more than two, light chain V and J or rearranged V/J sequences. Fertile male mice that express antibodies with universal light chains and humanized heavy chains are provided. Methods and compositions for making bispecific binding proteins are provided.Type: ApplicationFiled: May 2, 2022Publication date: December 15, 2022Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow
-
Publication number: 20220386575Abstract: The invention provides a genetically modified non-human animal that comprises in its genome unrearranged T cell receptor variable gene loci, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified non-human animal and methods of making the same. Various methods of using the genetically modified non-human animal are also provided.Type: ApplicationFiled: July 22, 2022Publication date: December 8, 2022Inventors: Lynn Macdonald, Andrew J. Murphy, John McWhirter, Naxin Tu, Vera Voronina, Cagan Gurer, Karolina Meagher, Sean Stevens
-
Publication number: 20220330532Abstract: The present disclosure provides, among other things, genetically modified non-human animals whose germline genome comprises an engineered endogenous immunoglobulin ? light chain locus comprising a single rearranged human immunoglobulin ? light chain variable region operably linked to a non-human C? gene segment, where the single rearranged human immunoglobulin ? light chain variable region comprises a human V? gene segment and a human J? gene segment. All immunoglobulin ? light chains expressed by B cells of the genetically modified non-human animal include human immunoglobulin ? light chain variable domains expressed from the single rearranged human immunoglobulin ? light chain variable region or a somatically hypermutated version thereof. Such animals, tissues from such animals, and cells from such animals represent an effective platform for producing antibodies, e.g., bispecific antibodies.Type: ApplicationFiled: June 4, 2020Publication date: October 20, 2022Inventors: John McWhirter, Johanna Hansen, Robert Babb, Chunguang Guo, Lynn Macdonald, Andrew J. Murphy
-
Publication number: 20220252837Abstract: A laser system including a laser source that generates a laser beam and an optical switch that receives the laser beam and selectively sends the laser beam to either a fast path or a slow path, wherein in the fast path the laser beam has a first F/# and in the slow path the laser beam has a second F/# that is higher in value that of the first F/#. The laser system further including an afocal optical system that is in the slow path and receives the laser beam from the optical switch and an x-y scanner that receives either a first laser beam from the slow path or a second laser beam from the fast path. The laser system including a scan lens system that receives a scanning laser beam from the x-y scanner and performs a z-scan for the scanning laser beam only in the case wherein the scanning laser beam is generated from the laser beam in the fast path. The laser system further including an aspheric patient interface device that receives a laser beam from the scan lens system.Type: ApplicationFiled: April 25, 2022Publication date: August 11, 2022Applicant: Lensar, Inc.Inventors: John McWhirter, Rudolph W. Frey, George C. Curatu, Steven E. Bott
-
Publication number: 20220217955Abstract: Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and/or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.Type: ApplicationFiled: December 8, 2021Publication date: July 14, 2022Inventors: John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy
-
Publication number: 20220195014Abstract: Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest. The anchor-modified immunoglobulin polypeptides are generally characterized at the N-terminus with an anchor, e.g., the receptor binding portion of a ligand that binds a receptor. Non-human animals genetically modified with recombinant immunoglobulin segments that encode the anchor-modified immunoglobulin polypeptides are capable of making the anchor-modified immunoglobulin polypeptides. Such non-human animals also provided, along with methods and compositions for making and using the non-human animals. Methods for producing anchor-modified immunoglobulins from non-human animals are also provided, as well as anchor-modified immunoglobulins generated therefrom.Type: ApplicationFiled: December 20, 2021Publication date: June 23, 2022Inventors: Jason Mastaitis, Andrew J. Murphy, John McWhirter, Vera Voronina, Jesper Gromada